Sensei Biotherapeutics company info

What does Sensei Biotherapeutics do?
Sensei Biotherapeutics (NASDAQ:SNSE) is a biopharmaceutical company focused on the development of next-generation immunotherapies for cancer and infectious diseases. The company's work revolves around its proprietary ImmunoPhage™ platform and its novel monoclonal antibody and T-cell receptor discovery platform, aimed at tailoring treatments to harness the body's immune system more effectively. Their pipeline includes multiple projects in various stages of research and clinical development, designed to achieve better outcomes for patients with unmet medical needs. Sensei Biotherapeutics is on a mission to transform cancer treatment paradigms and improve patient lives through groundbreaking scientific innovation.
Sensei Biotherapeutics company media
Company Snapshot

Is Sensei Biotherapeutics a public or private company?

key
Ownership
Public

How many people does Sensei Biotherapeutics employ?

people
Employees
27

What sector is Sensei Biotherapeutics in?

pie chart
Sector
Health Care

Where is the head office for Sensei Biotherapeutics?

location pin
Head Office
Rockville, United States

What year was Sensei Biotherapeutics founded?

founded flag
Year Founded
1999
What does Sensei Biotherapeutics specialise in?
/Cancer Therapies /Immuno-Pharmacotherapy /Biotechnology Research /Pharmaceutical Development /Biopharmaceutical Manufacturing /Clinical Trials

What are the products and/or services of Sensei Biotherapeutics?

Overview of Sensei Biotherapeutics offerings
Immuno-oncology therapeutics harnessing the immune system to fight cancer, focusing on novel treatments for various tumor types.
VISTA checkpoint inhibitors targeting the V-set immunoregulatory domain to augment cancer immunotherapy efficacy.
Precision medicine approach, using genomic data to tailor unique treatment strategies for cancer patients.
Research on bacteriophage-based vaccines aimed at stimulating the immune system against cancer.
Pipeline of monoclonal antibodies designed for specific tumor-associated antigens, improving targeted therapy options.
Collaborative research partnerships with academic institutions and biotech firms to speed up the development of innovative cancer treatments.

Who is in the executive team of Sensei Biotherapeutics?

Sensei Biotherapeutics leadership team
  • Mr. John K. Celebi M.B.A.
    Mr. John K. Celebi M.B.A.
    President, CEO & Director
  • Dr. Edward  Van der Horst Ph.D.
    Dr. Edward Van der Horst Ph.D.
    Chief Scientific Officer
  • Ms. Lora  Pike
    Ms. Lora Pike
    Vice President of Investor Relations & Communications
  • Mr. Christopher W. Gerry J.D.
    Mr. Christopher W. Gerry J.D.
    Senior VP, General Counsel & Secretary
  • Ms. Stephanie  Krebs M.B.A., M.S.
    Ms. Stephanie Krebs M.B.A., M.S.
    Chief Business Officer
  • Dr. Aaron  Weitzman FACP, M.D., Ph.D.
    Dr. Aaron Weitzman FACP, M.D., Ph.D.
    Chief Medical Officer